These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 23290985)

  • 1. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
    Dick AD; Tugal-Tutkun I; Foster S; Zierhut M; Melissa Liew SH; Bezlyak V; Androudi S
    Ophthalmology; 2013 Apr; 120(4):777-87. PubMed ID: 23290985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Mazurov V; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Mpofu S
    Ann Rheum Dis; 2013 Jun; 72(6):863-9. PubMed ID: 22730366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
    N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
    Srivastava SK; Watkins TR; Nguyen QD; Sharma S; Scales DK; Dacey MS; Shah RE; Chu DS; Grewal DS; Faia LJ; Suhler EB; Genovese MC; Guo Y; Barchuk WT; Besuyen R; Dick AD; Rosenbaum JT
    JAMA Ophthalmol; 2024 Sep; 142(9):789-797. PubMed ID: 39023880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
    Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
    Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
    Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
    Sepah YJ; Sadiq MA; Chu DS; Dacey M; Gallemore R; Dayani P; Hanout M; Hassan M; Afridi R; Agarwal A; Halim MS; Do DV; Nguyen QD
    Am J Ophthalmol; 2017 Nov; 183():71-80. PubMed ID: 28887113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab in Patients with Active Noninfectious Uveitis.
    Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
    N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.